Clinical factors predicting nemolizumab response in atopic dermatitis

Clinical predictors of response to nemolizumab, an anti-IL-31 receptor A antibody, were evaluated in patients with atopic dermatitis (AD). In a retrospective study of 14 Japanese patients, longer disease duration was significantly associated with poor response to treatment. While serum IgE levels and baseline Eczema Area Severity Index (EASI) scores alone were not predictive, their combination with disease duration improved discrimination between responders and nonresponders. Disease duration, serum IgE levels, and baseline EASI scores can be useful to predict nemolizumab efficacy in AD.